Adding abiraterone to standard treatment improves prostate cancer survival by 40 percent
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one...
Adding abiraterone to hormone therapy at the start of treatment for prostate cancer improves survival by 37 per cent, according to the results of one...
The immunotherapy drug pembrolizumab--already FDA-approved for other forms of cancer-has been found to be effective in patients with metastatic triple negative breast cancer, according to...
Credit: Penn Medicine CHICAGO -- Six years ago an international team of physician scientists known as BRCA-TAC led a charge to advance clinical testing of...
New Orleans, LA - June 4, 2017 -Research presented at the ASM Microbe 2017 meeting by Bryan Sanchez of California State University-Northridge in Northridge, Calif.,...
ASCO Perspective "Online technologies have transformed communications in practically every aspect of our lives, and now we're seeing they're also allowing patients to take an...
ASCO Perspective "This study provides strong evidence to support adding abiraterone to standard hormone therapy, primarily for men with metastatic prostate cancer," said Sumanta Kumar...
ASCO Perspective "These long-awaited findings show that this new class of treatment can deliver better results for women with BRCA-positive breast cancer," said ASCO President...
ASCO Perspective "Though the study is small and early, it demonstrates compelling evidence that may pave the way for a new class of drugs for...
ASCO Perspective "We continue to see promising reports about possible uses of circulating tumor DNA analysis. While this approach has a ways to go before...
Credit: Brian Strickland/UNC Lineberger CHICAGO-Cancer patients who reported their symptoms to their cancer care providers using a web-based survey lived longer than those patients who...
ASCO Perspective "This study gives more validation for the use of genomics in clinical practice and shows it could very well guide treatment choices for...
ASCO Perspective "Perhaps no other area of oncology has seen such dramatic progress in treatment over the past decades as childhood cancer. As a result...
CHICAGO - High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...
New Orleans, LA - June 4, 2017 - Findings from a study that looked at susceptibility trends of Staphylococcus aureus in U.S. hospital patients showed...
New Orleans, LA - June 4, 2017 -Research presented at ASM Microbe 2017 by experts at the Fertility and Cryogenics Lab shows a reliable clinical...
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.